Immunovant (IMVT) Capital Expenditures (2019 - 2026)

Immunovant (IMVT) has 8 years of Capital Expenditures data on file, last reported at -$69000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 100.96% year-over-year to -$69000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69000.0 (down 100.89% YoY) and the FY2026 annual result came in at -$69000.0, down 100.89% from the prior year.
• Capital Expenditures retreated to -$69000.0 in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $7.9 million in Q3 2024 to a low of -$7.5 million in Q4 2024.
• A 5-year average of $641692.3 and a median of $45000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 245.16% — and 2024, when it soared 17631.11%.
• Tracing IMVT's Capital Expenditures over 5 years: stood at $98000.0 in 2022, then plunged by 145.92% to -$45000.0 in 2023, then plunged by 16595.56% to -$7.5 million in 2024, then surged by 195.54% to $7.2 million in 2025, then sank by 100.96% to -$69000.0 in 2026.
• The last three Capital Expenditures figures came in at -$69000.0 (Q1 2026), $7.2 million (Q1 2025), and -$7.5 million (Q4 2024), per Business Quant data.